| scholarly article | Q13442814 |
| P50 | author | Tamara Alliston | Q42088746 |
| Jeremy O Jones | Q78720330 | ||
| P2093 | author name string | Leila Su | |
| Dan Nguyen | |||
| Maya Otto-Duessel | |||
| Miaoling He | |||
| Minyoung Lim | |||
| Emily Chin | |||
| P2860 | cites work | Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor | Q24319189 |
| Glucocorticoid receptor homodimers and glucocorticoid-mineralocorticoid receptor heterodimers form in the cytoplasm through alternative dimerization interfaces | Q24551024 | ||
| From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells | Q24682910 | ||
| A surface on the androgen receptor that allosterically regulates coactivator binding | Q27648698 | ||
| Cancer statistics, 2013 | Q27860762 | ||
| A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth | Q28116222 | ||
| Molecular determinants of resistance to antiandrogen therapy | Q28236889 | ||
| Androgen and glucocorticoid receptor heterodimer formation. A possible mechanism for mutual inhibition of transcriptional activity | Q28238939 | ||
| Steroid receptor heterodimerization demonstrated in vitro and in vivo | Q28571816 | ||
| Increased survival with enzalutamide in prostate cancer after chemotherapy | Q29617511 | ||
| Small-molecule inhibitors of protein-protein interactions: progressing towards the dream | Q29617758 | ||
| Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer | Q30485336 | ||
| Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant | Q30495758 | ||
| Beta-catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcription | Q33292178 | ||
| Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. | Q33770362 | ||
| Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer | Q33823702 | ||
| Distinct glucocorticoid receptor transcriptional regulatory surfaces mediate the cytotoxic and cytostatic effects of glucocorticoids | Q33958788 | ||
| Novel irreversible small molecule inhibitors of replication protein A display single-agent activity and synergize with cisplatin | Q33994331 | ||
| Cell- and gene-specific regulation of primary target genes by the androgen receptor | Q34005736 | ||
| Signal transduction and transcriptional regulation by glucocorticoid receptor-LexA fusion proteins | Q34163692 | ||
| Regulation of expanded polyglutamine protein aggregation and nuclear localization by the glucocorticoid receptor | Q34973238 | ||
| Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model | Q35209369 | ||
| Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants | Q35249697 | ||
| Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence | Q35645358 | ||
| Androgen receptor cross-talk with cell signalling pathways | Q35934837 | ||
| Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal | Q36003940 | ||
| Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α | Q36926447 | ||
| Target deconvolution strategies in drug discovery | Q36961595 | ||
| Pathologic effects of testosterone deprivation | Q36964257 | ||
| Proteomic methods for drug target discovery | Q37087549 | ||
| Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance | Q37145531 | ||
| Non-competitive androgen receptor inhibition in vitro and in vivo. | Q37182710 | ||
| Structural basis of androgen receptor binding to selective androgen response elements. | Q37414946 | ||
| Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease | Q37469444 | ||
| Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines | Q39250655 | ||
| Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression | Q39605639 | ||
| Runx2 regulates survivin expression in prostate cancer cells | Q39769098 | ||
| Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer | Q40105462 | ||
| The androgen receptor: an overview. | Q40734794 | ||
| Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. | Q40812297 | ||
| Target identification using drug affinity responsive target stability (DARTS) | Q42959458 | ||
| Effects of selective androgen receptor modulator (SARM) treatment in osteopenic female rats. | Q43281529 | ||
| Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy | Q43980991 | ||
| HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability | Q45149773 | ||
| Mechanisms of androgen receptor activation in advanced prostate cancer: differential co-activator recruitment and gene expression. | Q46882539 | ||
| The Androgen Receptor Gene Mutations Database | Q73943347 | ||
| p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6 | Q78386054 | ||
| A cellular conformation-based screen for androgen receptor inhibitors | Q81529840 | ||
| Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer | Q85054415 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 692-702 | |
| P577 | publication date | 2014-01-03 | |
| P1433 | published in | ACS Chemical Biology | Q165583 |
| P1476 | title | Ligand-independent and tissue-selective androgen receptor inhibition by pyrvinium | |
| P478 | volume | 9 |
| Q38711524 | Androgen inhibits key atherosclerotic processes by directly activating ADTRP transcription |
| Q38350089 | Are androgen receptor variants a substitute for the full-length receptor? |
| Q53126460 | Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor-Chromatin Interactions. |
| Q49922188 | Complex HuR function in pancreatic cancer cells |
| Q35548750 | Drug affinity responsive target stability (DARTS) for small-molecule target identification |
| Q64253591 | Mechanistic Investigation of the Androgen Receptor DNA-Binding Domain Inhibitor Pyrvinium |
| Q34365632 | Molecular pathways and targets in prostate cancer |
| Q60015421 | Molecules targeting the androgen receptor (AR) signaling axis beyond the AR-Ligand binding domain |
| Q34495028 | Recent advances in allosteric androgen receptor inhibitors for the potential treatment of castration-resistant prostate cancer. |
| Q34249190 | Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer |
| Q38698469 | Synthesis and evaluation of novel thiazole-based derivatives as selective inhibitors of DNA-binding domain of the androgen receptor. |
| Q89947575 | Targeting the CK1α/CBX4 axis for metastasis in osteosarcoma |
| Q38684406 | The novel role of pyrvinium in cancer therapy. |
Search more.